CV DEATH HAS A NEW OPPONENT
CV DEATH HAS A NEW OPPONENT

Use of Empagliflozin Jardiance in HF patients with Low eGFR

Document ID: PC-PH-104057

06/12/2022

Author: Boehringer Ingelheim

Related content

 
PC-PH-104057
Production date: Dec 2022